Osteoporosis Drugs Market To Reach $18.80 Billion By 2030

Osteoporosis Drugs Market Growth & Trends

The global osteoporosis drugs market size is expected to reach USD 18.80 billion by 2030 and is projected to grow at a CAGR of 3.5% from 2024 to 2030, according to a new report by Grand View Research, Inc. An upsurge rise in the unhealthy lifestyle adoption has resulted in aggravation and increase in the prevalence of osteoporosis which is presumed to propel the osteoporosis drugs market during the forecast period.

In addition, growing number of patent expiries is fueling the high clinical urgency to use generic versions of the established drugs, which is presumed to fuel generic osteoporosis drugs market during the forecast period. The aforementioned factors cumulatively are slated to present the with high potential growth opportunities over the coming years.

Furthermore, rising number of initiatives to increase the awareness levels pertaining to osteoporosis care amongst the patients as well as the physicians is expected to widen the osteoporosis market growth potential during the forecast period. For instance, National Osteoporosis Foundation (NOF), a healthcare organization responsible for National Bone Health Alliance and Fracture Liaison Service (FLS) care coordination programs that focuses on elevating awareness levels as well as provides training to healthcare professionals

 Request a free sample copy or view report summary: Osteoporosis Drugs Market Report

Osteoporosis Drugs Market Report Highlights

• Branded drugs held the dominant share of the product segment in 2023. The dominant share can be attributed to extensive utilization of bisphosphates, rank ligand inhibitors for the treatment of osteoporosis, possessing high efficacy

• Generics are expected to witness at a lucrative CAGR owing to consistent patent expiries over the coming years as well as high clinical urgency for inexpensive medication in the emerging economies

• In 2023, North America accounted for the largest share in the global osteoporosis drugs market owing to the presence of established companies extensively involved in the commercialization of branded therapeutics

• Asia Pacific is anticipated to grow at an exponential CAGR as a consequence of favorable government initiatives promoting information pertaining to osteoporosis care

• The key participants are employing sustainability strategies promoting the adoption of osteoporosis therapeutics to gain competitive advantage. For instance, Actavis Inc. announced to acquire Warner Chilcott PLC in order to widen their product portfolio

Osteoporosis Drugs Market Segmentation

Grand View Research has segmented the global osteoporosis drugs market report based on drug class, type, distribution channel, and region

Osteoporosis Drugs Class Outlook (Revenue, USD Million, 2018 - 2030)

• Branded

• Generic

Osteoporosis Drugs Type Outlook (Revenue, USD Million, 2018 - 2030)

• Bisphosphonates

• Parathyroid Hormone

• Calcitonin

• Selective Estrogen Inhibitor Modulator

• Rank Ligand Inhibitor

• Others

Osteoporosis Drugs Distribution Channel Outlook (Revenue, USD Million, 2018 - 2030)

• Hospital Pharmacy

• Retail Pharmacy

• Online Pharmacy

Osteoporosis Drugs Regional Outlook (Revenue, USD Million, 2018 - 2030)

• North America

  • U.S.

  • Canada

  • Mexico

• Europe

  • Germany

  • UK

  • France

  • Italy

  • Spain

  • Denmark

  • Sweden

  • Norway

• Asia Pacific

  • China

  • Japan

  • India

  • South Korea

  • Australia

  • Thailand

• Latin America

  • Brazil

  • Argentina

• Middle East and Africa (MEA)

  • Saudi Arabia

  • UAE

  • South Africa

  • Kuwait

List of Key Players of Osteoporosis Drugs Market

• Amgen Inc.

• Eli Lilly and Company

• Merck & Co., Inc.

• Novartis International AG

• Pfizer Inc.

• GlaxoSmithKline plc

• Radius Health, Inc.

• UCB S.A.

• Teva Pharmaceutical Industries Ltd.

• Roche Holding AG